Shanghai Hutchmed announced it is starting a Phase III combination trial of its surufatinib and Junshi's PD-1 in patients with advanced neuroendocrine carcinoma (NEC). Hutchmed's Sulanda® (surufatinib), an anti-angiogenesis EFGR kinase inhibitor, and Junshi's Tuoyi® (toripalimab) immunotherapy are both approved in China . In a Phase II trial, the combination produced an objective response rate of 20% and disease control rate of 70%. Median progression-free survival was 3.9 months. More details.... Stock Symbols: (NSDQ/AIM: HCM; HK: 13) Share this with colleagues: // //